Stocks · News reference
JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on Medline, Lowers Price Target to $43
Bragar Eagel & Squire, P.C. is Investigating Medline Inc. on Behalf of Medline Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Medline Inc. for potential securities law violations following FDA warning letters regarding manufacturing practice violations. The company's stock declined 7.2% on June 2, 2026 after FDA warnings and another 12.8% on August 5, 2026 after the company disclosed earnings losses from remediation efforts including product recalls.
MEDLINE INC. INVESTIGATION: MDLN Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Law firm Kirby McInerney LLP is investigating Medline Inc. for potential federal securities law violations following an FDA warning letter in June 2026 detailing significant manufacturing practice violations. The company's stock declined 7.2% on the FDA announcement and another 12.8% in August after Medline disclosed earnings losses from remediation efforts including product recalls.